Paraneoplastic sensory ganglionopathy

Paraneoplastic sensory ganglionopathy (also known as paraneoplastic sensory neuronopathy or paraneoplastic dorsal root ganglionopathy) is a rare neurological condition that occurs as a remote effect of cancer, most commonly small cell lung cancer, though it can also be associated with breast cancer, ovarian cancer, lymphoma, and other malignancies. It is classified as a paraneoplastic neurological syndrome, meaning it is caused by an immune-mediated attack on the nervous system triggered by the presence of a tumor, rather than by direct tumor invasion. The condition specifically targets the dorsal root ganglia — clusters of sensory nerve cell bodies located along the spinal cord — leading to progressive destruction of sensory neurons. The hallmark symptoms include asymmetric or multifocal sensory loss, painful paresthesias (tingling or burning sensations), numbness, and sensory ataxia (impaired coordination due to loss of proprioception, or position sense). Patients often experience difficulty walking, pseudoathetoid movements of the hands, and loss of deep tendon reflexes. The upper and lower limbs are typically affected, and symptoms may progress over weeks to months, sometimes preceding the cancer diagnosis by months or even years. The condition is strongly associated with anti-Hu antibodies (also called ANNA-1, or anti-neuronal nuclear antibody type 1), which are found in the majority of cases and serve as an important diagnostic biomarker. Treatment of paraneoplastic sensory ganglionopathy is challenging. The primary approach involves treating the underlying malignancy, which may stabilize or occasionally improve neurological symptoms. Immunotherapy, including intravenous immunoglobulins, plasma exchange, corticosteroids, or rituximab, has been attempted with variable and often limited success, particularly if treatment is delayed. Early diagnosis and prompt cancer treatment offer the best chance of stabilizing the neurological deficit. Symptomatic management of neuropathic pain with medications such as gabapentin, pregabalin, or duloxetine is an important component of care. Unfortunately, significant neuronal damage is often irreversible, and many patients are left with substantial disability.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Paraneoplastic sensory ganglionopathy